17,002 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Liberty Capital Management Inc.

Liberty Capital Management Inc. bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,002 shares of the medical research company’s stock, valued at approximately $8,524,000. Thermo Fisher Scientific comprises approximately 1.5% of Liberty Capital Management Inc.’s investment portfolio, making the stock its 20th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after acquiring an additional 288,296 shares during the last quarter. J. Stern & Co. LLP increased its stake in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. State Street Corp raised its position in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Capital World Investors lifted its stake in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after buying an additional 26,425 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $588.17 on Monday. The company has a market cap of $217.48 billion, a price-to-earnings ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock’s 50-day moving average is $529.37 and its 200-day moving average is $508.75.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Morgan Stanley increased their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Finally, Barclays increased their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last quarter. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.